Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 62.2% in August

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 37,641 shares, a drop of 62.2% from the August 15th total of 99,687 shares. Based on an average daily volume of 175,579 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Biorestorative Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of BRTX. Virtu Financial LLC raised its holdings in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after acquiring an additional 12,319 shares during the last quarter. Citadel Advisors LLC purchased a new position in Biorestorative Therapies in the 3rd quarter worth approximately $152,000. Finally, DRW Securities LLC acquired a new position in shares of Biorestorative Therapies during the 4th quarter worth approximately $55,000. 69.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, August 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biorestorative Therapies has a consensus rating of “Sell”.

Biorestorative Therapies Trading Down 3.3%

BRTX traded down $0.09 on Friday, hitting $2.67. 10,281 shares of the company’s stock were exchanged, compared to its average volume of 24,393. Biorestorative Therapies has a fifty-two week low of $2.61 and a fifty-two week high of $34.60. The firm has a 50-day moving average price of $4.84 and a 200-day moving average price of $5.43. The stock has a market cap of $3.68 million, a price-to-earnings ratio of -0.12 and a beta of 0.83.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.